Education
About Us
Working with TipRanks
Follow Us
ABLS - ETF AI Analysis
Top Page
Abacus FCF Small Cap Leaders ETF (ABLS)
Rating:69Neutral
Price Target:―
Positive Factors
Strong Top Holdings
Several top holdings, such as Argan and Collegium Pharmaceutical, have delivered strong year-to-date performance, supporting the fund’s returns.
Sector Diversification
The ETF spreads its investments across multiple sectors, including Technology, Health Care, and Industrials, reducing reliance on any single industry.
Low Expense Ratio
The fund’s expense ratio is relatively low, making it cost-effective compared to many other ETFs.
Negative Factors
Weak Overall Performance
The ETF has struggled recently, with negative returns across year-to-date, one-month, and three-month periods.
High U.S. Concentration
Nearly all of the fund’s assets are invested in U.S. companies, limiting exposure to international markets.
Underperforming Holdings
Some holdings, such as Tenable Holdings and Kontoor Brands, have posted negative year-to-date performance, dragging down the fund.
ABLS vs. SPDR S&P 500 ETF (SPY)
AUM1.17M
RegionNorth America
Expense Ratio0.39%
Beta0.70
IssuerAbacus
Inception DateFeb 18, 2025
Dividend YieldN/A
Asset ClassEquity
Index TrackedAbacus FCF Small Cap Leaders Index - Benchmark TR Gross
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume36
30 Day Avg. Volume38
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
28.57Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering50
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ABLS Summary
The Abacus FCF Small Cap Leaders ETF (ABLS) is an investment fund that focuses on small-cap companies in the U.S. market. It includes firms with strong financial health, such as robust cash flow and profitability, and follows the Abacus FCF Small Cap Leaders Index. Some of its top holdings include PJT Partners and Artisan Partners. Investors might consider ABLS for diversification and the potential growth of small-cap stocks. However, it’s important to note that small-cap stocks can be more volatile than larger companies, meaning their prices can rise and fall quickly.
How much will it cost me?The Abacus FCF Small Cap Leaders ETF (ABLS) has an expense ratio of 0.39%, meaning you’ll pay $3.90 per year for every $1,000 invested. This is slightly higher than average for passively managed ETFs because it focuses on a niche area of small-cap stocks with strong financial metrics.
What would affect this ETF?The Abacus FCF Small Cap Leaders ETF could benefit from strong growth in the U.S. economy, particularly in sectors like technology and health care, which make up a significant portion of its holdings. However, it may face challenges if interest rates rise, as small-cap companies often rely on borrowing to fund growth, or if economic conditions weaken, which could impact consumer spending and industrial activity. Regulatory changes in key sectors like financials or health care could also influence performance positively or negatively.
ABLS Top 10 Holdings
The Abacus FCF Small Cap Leaders ETF leans heavily into technology and healthcare, which together make up over half of its portfolio. Argan, a top holding, has shown mixed momentum, with strong growth potential tempered by valuation concerns. Collegium Pharmaceutical and Enova International are rising stars, benefiting from robust financial performance and strategic initiatives. However, CommVault Systems and Artisan Partners are lagging, weighed down by bearish trends and valuation challenges. With its U.S.-focused small-cap strategy, the fund is a blend of innovation and risk, driven by sector-specific dynamics.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Argan | 8.25% | $96.84K | $4.55B | 127.45% | 73 Outperform | |
| Collegium Pharmaceutical | 5.28% | $62.02K | $1.57B | 71.21% | 71 Outperform | |
| CommVault Systems | 4.31% | $50.62K | $5.61B | -16.48% | 65 Neutral | |
| Artisan Partners | 3.83% | $44.91K | $3.37B | -4.89% | 73 Outperform | |
| Enova International | 3.56% | $41.83K | $4.08B | 68.41% | 71 Outperform | |
| LCI Industries | 3.22% | $37.76K | $3.00B | 20.47% | 79 Outperform | |
| Harmony Biosciences Holdings | 3.20% | $37.53K | $2.22B | 11.49% | 81 Outperform | |
| PJT Partners | 2.98% | $34.98K | $8.34B | 7.96% | 71 Outperform | |
| Healthcare Services | 2.64% | $30.95K | $1.38B | 70.40% | 72 Outperform | |
| Progyny | 2.63% | $30.92K | $2.20B | 52.66% | 79 Outperform |
ABLS Technical Analysis
Positive
―
Price Trends
23.09
Positive
23.23
Positive
23.02
Positive
Market Momentum
0.06
Positive
52.43
Neutral
49.04
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For ABLS, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 23.24, equal to the 50-day MA of 23.09, and equal to the 200-day MA of 23.02, indicating a bullish trend. The MACD of 0.06 indicates Positive momentum. The RSI at 52.43 is Neutral, neither overbought nor oversold. The STOCH value of 49.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ABLS.
ABLS Peer Comparison
Comparison Results
Performance Comparison
ABLS
Abacus FCF Small Cap Leaders ETF
23.28
-1.14
-4.67%
FLQS
Franklin LibertyQ U.S. Small Cap Equity ETF
―
―
―
AFSM
First Trust Active Factor Small Cap ETF
―
―
―
STXK
Strive 2000 ETF
―
―
―
FSCC
Federated Hermes MDT Small Cap Core ETF
―
―
―
BKSE
BNY Mellon US Small Cap Core Equity ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents